MIT has entered a collaborative partnership with Sigilon Therapeutics to create programmable cell therapeutics to treat chronic illnesses and diseases such as hemophilia and lysosomal storage diseases.
MIT to develop programmable cell therapies with Sigilon
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.